Day One Biopharmaceuticals’ (DAWN) “Outperform” Rating Reaffirmed at Wedbush

Wedbush reaffirmed their outperform rating on shares of Day One Biopharmaceuticals (NASDAQ:DAWN) in a research report sent to investors on Wednesday morning, RTT News reports. The firm currently has a $33.00 target price on the stock. Wedbush also issued estimates for Day One Biopharmaceuticals’ Q3 2025 earnings at ($0.32) EPS and FY2025 earnings at ($1.40) EPS.

DAWN has been the subject of a number of other reports. Needham & Company LLC upped their price target on Day One Biopharmaceuticals from $30.00 to $33.00 and gave the company a buy rating in a report on Wednesday. Piper Sandler reaffirmed an overweight rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Tuesday, March 26th. Oppenheimer reaffirmed a market perform rating on shares of Day One Biopharmaceuticals in a report on Tuesday, February 27th. The Goldman Sachs Group lowered their price target on Day One Biopharmaceuticals from $50.00 to $44.00 and set a buy rating for the company in a report on Tuesday, February 27th. Finally, JPMorgan Chase & Co. upped their price target on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an overweight rating in a report on Monday, April 22nd. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of Moderate Buy and an average target price of $39.33.

Day One Biopharmaceuticals Stock Performance

DAWN stock opened at $14.92 on Wednesday. The company’s 50 day moving average price is $15.22 and its 200 day moving average price is $13.83. Day One Biopharmaceuticals has a fifty-two week low of $9.67 and a fifty-two week high of $17.85. The firm has a market capitalization of $1.30 billion, a price-to-earnings ratio of -6.27 and a beta of -1.48.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Monday, February 26th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). Equities analysts forecast that Day One Biopharmaceuticals will post -2.67 EPS for the current fiscal year.

Insider Activity

In related news, insider Samuel C. Blackman sold 20,000 shares of the stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $16.11, for a total transaction of $322,200.00. Following the completion of the sale, the insider now directly owns 1,224,662 shares of the company’s stock, valued at $19,729,304.82. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, insider Samuel C. Blackman sold 20,000 shares of the stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $16.11, for a total transaction of $322,200.00. Following the completion of the sale, the insider now directly owns 1,224,662 shares of the company’s stock, valued at $19,729,304.82. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Samuel C. Blackman sold 2,258 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $34,434.50. Following the sale, the insider now directly owns 1,244,662 shares of the company’s stock, valued at $18,981,095.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 55,781 shares of company stock valued at $883,160. 8.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Hennion & Walsh Asset Management Inc. raised its position in Day One Biopharmaceuticals by 2.5% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 59,289 shares of the company’s stock worth $979,000 after acquiring an additional 1,445 shares in the last quarter. Fisher Asset Management LLC raised its position in Day One Biopharmaceuticals by 89.0% in the fourth quarter. Fisher Asset Management LLC now owns 68,446 shares of the company’s stock worth $999,000 after acquiring an additional 32,238 shares in the last quarter. Wellington Management Group LLP raised its position in Day One Biopharmaceuticals by 77.7% in the fourth quarter. Wellington Management Group LLP now owns 208,969 shares of the company’s stock worth $3,051,000 after acquiring an additional 91,393 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Day One Biopharmaceuticals by 28.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock worth $30,935,000 after acquiring an additional 472,654 shares in the last quarter. Finally, Quintet Private Bank Europe S.A. raised its position in Day One Biopharmaceuticals by 43.2% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after acquiring an additional 1,000 shares in the last quarter. 87.95% of the stock is owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.